Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at genetic factors that affect how breast cancer grows and develops (GENFABRCA)

Overview

Cancer types:

Breast cancer

Status:

Results

Phase:

Other

Details

This study was looking at genetic factors that might affect how breast cancer cells develop, grow and respond to treatment.

Many breast cancers respond very well to treatment. But this is not always the case and sometimes breast cancer comes back. Doctors want to understand more about why this happens.

In this study, researchers were looking at differences in from women with advanced breast cancer. The aim of the study was to try and find out how genetic factors may affect

  • How breast cancer develops

  • Why some breast cancers grow more quickly than others

  • How well different breast cancers respond to treatment

In the long term this may help doctors improve the treatment for breast cancer.

Recruitment start: 1 April 2005

Recruitment end: 31 March 2009

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Prof Angela Cox

Supported by

Experimental Cancer Medicine Centre (ECMC)

National Institute for Health Research Cancer Research Network (NCRN)

Weston Park Hospital Cancer Appeal

Last reviewed: 25 Mar 2014

CRUK internal database number: 758

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.